Richard B. Lipton, M.D., is the Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine, where he also directs the Montefiore Headache Center. He is a diplomate of the American Board of Psychiatry and Neurology, a fellow of the American Academy of Neurology and UCNS certified in headache medicine. Dr. Lipton has published more than 1100 articles in indexed journals and serves on the editorial boards of several journals, including Neurology. He is a six-time winner of the H.G. Wolff Award for excellence in headache research from the American Headache Society (AHS) and a two-time winner of the Enrico Greppi award from the European Headache Federation. He is a Past-President of the American Headache Society.
He earned his medical degree at the University of Chicago Pritzker School of Medicine. After a medical internship at Northwestern Memorial Hospital, he completed his neurology residency and clinical neurophysiology fellowship at the Albert Einstein College of Medicine. He also completed a fellowship in neuroepidemiology at Columbia University.
Course Summary:
This lecture will summarize recently approved acute treatments for migraine, including newer molecular entities such as gepants, (CGRP small molecule receptor blockers) and ditans (5HT1f receptor agonists), as well as new takes on older medications including novel formulations of NSAIDs, triptans, dihydroergotamine and combination products. We will consider an approach to prioritizing and individualizing acute treatments based on patient needs. Next, we will consider the opportunities created when the same agent can be used as both an acute and as a preventive treatment. These opportunities include simultaneously using the same medication as both a preventive treatment and as an acute treatment as well as shifting between acute and preventive treatment for a particular patient based on treatment needs. In addition, early treatment approaches include treating while pain is mild, treating during the prodrome, and treating in periods of increased short-term risk of headache before symptoms develop (situational prevention).
Learning Objectives:
1.Be able to optimize the choice of acute treatments for migraine, particularly newer molecular entities such as gepants and on the ditans.
2.Instruct patients on the use of acute treatment to optimize their value.
3.Describe emerging treatment approaches, including treatment during mild pain, treatment during the prodromal phase, and treating in periods of high risk for headache (situational prevention).
He earned his medical degree at the University of Chicago Pritzker School of Medicine. After a medical internship at Northwestern Memorial Hospital, he completed his neurology residency and clinical neurophysiology fellowship at the Albert Einstein College of Medicine. He also completed a fellowship in neuroepidemiology at Columbia University.
Course Summary:
This lecture will summarize recently approved acute treatments for migraine, including newer molecular entities such as gepants, (CGRP small molecule receptor blockers) and ditans (5HT1f receptor agonists), as well as new takes on older medications including novel formulations of NSAIDs, triptans, dihydroergotamine and combination products. We will consider an approach to prioritizing and individualizing acute treatments based on patient needs. Next, we will consider the opportunities created when the same agent can be used as both an acute and as a preventive treatment. These opportunities include simultaneously using the same medication as both a preventive treatment and as an acute treatment as well as shifting between acute and preventive treatment for a particular patient based on treatment needs. In addition, early treatment approaches include treating while pain is mild, treating during the prodrome, and treating in periods of increased short-term risk of headache before symptoms develop (situational prevention).
Learning Objectives:
1.Be able to optimize the choice of acute treatments for migraine, particularly newer molecular entities such as gepants and on the ditans.
2.Instruct patients on the use of acute treatment to optimize their value.
3.Describe emerging treatment approaches, including treatment during mild pain, treatment during the prodromal phase, and treating in periods of high risk for headache (situational prevention).
1 AMA PRA Category 1 Credit ™
To receive a Continuing Medical Education certificate, complete the pre-test, attend the presentation, complete the post-test, and the post-presentation evaluation.
To receive a Continuing Medical Education certificate, complete the pre-test, attend the presentation, complete the post-test, and the post-presentation evaluation.